Lipitor II
Executive Summary
After hosting delegations of licensing hopefuls for its phase III Cox-2 inhibitor, Searle chose Pfizer Inc., the industry's most aggressive and probably most successful co-promoter. Searle's next likely co-promotion announcements will concern its phase IIb/IIIa platelet inhibitors.
You may also be interested in...
Pfizer's Lipitor Sees Big Boost From Medicare
Pfizer is discounting its blockbuster brand Lipitor more aggressively. But, thanks to the economics of Medicare Part D, the product is still benefiting from a big net price increase in 2006. Lipitor's performance is some much needed good news for Pfizer--and maybe even better news for the industry as a whole.
FDA Panel Will Have To Weigh Pediatric Cancer Drug’s ‘Higher Level’ Of Uncertainty Against Rare, Devastating Disease
US WorldMeds NDA package for eflornithine for high-risk neuroblastoma provides “a higher level of uncertainty than is typically seen in oncology applications,” agency says. Though FDA seems largely satisfied with the sponsor’s externally controlled study, confirmatory evidence may be lacking.
Novo Files Suit Over IRA As It Joins Others In Signing On To Price Negotiations
The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Reduction Act program with Novo’s recent complaint, which objects to the aggregation of its insulin products.